PCI-34051 | MedChemExpress (MCE)
品牌 | 厂商性质 | 产地 | 货期 | 价格 |
---|---|---|---|---|
MedChemExpress (MCE) | 生产商 | 美国 | 现货 | 679 |
性能特点
PCI-34051 是一种有效的选择性的 HDAC8 抑制剂,IC50 为 10 nM。
规格 | CAS号 | 价格 | 操作 |
---|---|---|---|
10 mM * 1 mL | 950762-95-5 | ¥679.00 | 询底价 |
PCI-34051 产品活性:PCI-34051 是一种有效的选择性的 HDAC8 抑制剂,IC50 为 10 nM。 产品来源: https://www.medchemexpress.cn/PCI-34051.html 研究领域:Cell Cycle/DNA Damage | Epigenetics | Apoptosis 作用靶点:HDAC | Apoptosis In Vitro: PCI-34051 inhibits pure recombinant HDAC8 with Ki of 10 nM with >200-fold selectivity over the other HDACs tested, including HDACs 1, 2, 3, 6 and 10. PCI-34051 is derived from a low molecular weight hydroxamic acid scaffold that possessed promising potency (HDAC8; Ki=2 μM) and selectivity (approximately fivefold) for HDAC8 relative to the other class I HDACs. PCI-34051 is found to induce apoptosis at low micromolar concentrations in cell lines derived from T-cell lymphomas, including Jurkat and HuT78, whereas doses as high as 20 μM has no effect on B-cell- or myeloid-derived lymphomas or solid tumor lines. In Vivo: Administration of PCI-34051 and Dexamethasone reduces the eosinophilic inflammation and airway hyperresponsiveness in asthma to reduce the airway remodeling. 相关产品:Bioactive Compound Library Plus | Apoptosis Compound Library | Cell Cycle/DNA Damage Compound Library | Epigenetics Compound Library | Histone Modification Research Compound Library | Anti-Cancer Compound Library | Anti-Aging Compound Library | Reprogramming Compound Library | Oxygen Sensing Compound Library | Anti-Breast Cancer Compound Library | Anti-Pancreatic Cancer Compound Library | Anti-Blood Cancer Compound Library | Targeted Diversity Library | Anti-Liver Cancer Compound Library | Osteogenesis Compound Library | Highly Selective Inhibitors Library | Highly Selective Activators Library | Cell Death Library | Anti-Hematopathy Compound Library | Multi-Target Compound Library | Bioactive Compound Library Max | MG-132 | Doxorubicin hydrochloride | Bafilomycin A1 | Tamoxifen | Y-27632 | LY294002 | Paclitaxel | Z-VAD-FMK | Acetylcysteine | Angiotensin II human | 2-Deoxy-D-glucose | Staurosporine | Actinomycin D | SB-431542 | 5-Fluorouracil | Bortezomib | Deferoxamine mesylate | Oxaliplatin | Trametinib | Sorafenib | Temozolomide | Gemcitabine | Decitabine | Mdivi-1 | Rotenone | Etoposide | Elesclomol | Ruxolitinib | Monomethyl auristatin E | DAPT 品牌介绍: MCE (MedChemExpress) 拥有数百种全球独家化合物,我们致力于为全球科研客户提供最新最全的高品质小分子活性化合物;10,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领域;设有专业的实验中心和严格的质控、验证体系;提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告,确保产品的高纯度、高品质;产品的生物活性多经各国客户实验验证;Nature, Cell, Science 等多种顶级期刊及制药专利收录了MCE客户的科研成果;专业团队跟踪最新的制药及生命科学研究进展,为您提供全球最新的活性化合物;与世界各大制药公司及知名科研机构建立了长期的合作。
PCI-34051 | MedChemExpress (MCE)信息由MedChemExpress (MCE)为您提供,如您想了解更多关于PCI-34051 | MedChemExpress (MCE)报价、型号、参数等信息,欢迎来电或留言咨询。
注:该产品未在中华人民共和国食品药品监督管理部门申请医疗器械注册和备案,不可用于临床诊断或治疗等相关用途